NEUROTENSIN RECEPTOR LIGANDS
    6.
    发明公开

    公开(公告)号:EP3712131A1

    公开(公告)日:2020-09-23

    申请号:EP20166422.4

    申请日:2013-12-06

    摘要: The present invention is related to a compound of formula (I)

    wherein R 1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R 2 is selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C 2 -C 5 )alkylidene; R 3 , R 4 and R 5 are each and independently selected from the group consisting of hydrogen and (Ci-C4)alkyl under the proviso that one of R 3 , R 4 and R 5 is of the formula (II)

    wherein ALK' is (C 2 -C 5 )alkylidene; R 6 is selected from the group consisting of hydrogen and (C 1 -C 4 )alkyl; and R 7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.

    CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF
    10.
    发明公开
    CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF 审中-公开
    包含神经降压素受体配体的共轭物及其用途

    公开(公告)号:EP3154638A1

    公开(公告)日:2017-04-19

    申请号:EP15730392.6

    申请日:2015-06-10

    IPC分类号: A61P35/00 A61K47/50

    摘要: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK' is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (3) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.

    摘要翻译: 本发明涉及包含通式(1)[TM1] - [AD1] - [LM] - [AD2] - [TM2](1)的结构的缀合物,其中TM1是第一靶向部分,其中 第一靶向部分能够结合第一靶标,AD1是第一衔接头部分或不存在,LM是接头部分或不存在,AD2是第二衔接头部分或不存在,并且TM2是第二靶向部分,其中 第二靶向部分能够结合第二靶标; 其中所述第一靶向部分和/或所述第二靶向部分是式(2)的化合物:其中R 1选自氢,甲基和环丙基甲基; AA-COOH是选自2-氨基-2金刚烷羧酸,环己基甘氨酸和9-氨基 - 二环[3.3.1]壬烷-9羧酸的氨基酸; R2选自(C1-C6)烷基,(C3-C8)环烷基,(C3-C8)环烷基甲基,卤素,硝基和三氟甲基; ALK'是(C 2 -C 5)亚烷基; R3,R4和R5各自独立地选自氢和(C1-C4)烷基,条件是R3,R4和R5中的一个具有下式(3),其中ALK'是(C2-C5 )亚烷基; R6选自氢和(C1-C4)烷基; R7是一个键; 或其药理学可接受的盐,溶剂化物或水合物。